Philippines Pharmacovigilance: Comparison of Philippines FDA and VAERS Foreign Reports for Ages 18 to 39. Peak Time-Linked SAE Occurred Immediately (0-1 Days) Following Injection.

Philippines FDA reports 361 suspected deaths, with no other breakdowns of AEFI. The US FDA contains reports of 2,206 Filipino Serious Adverse Events for This Age-Group, with 261 deaths.

Persons aged 18 to 39 are in the prime of their lives. They were generally considered low risk for Covid-19 infection complications. This age-group was offered vaccine products from 1st March 2021 if they were working in healthcare or were front-liner workers, and by mid-year for the general population.

Philippines FDA Pharmacovigilance Reporting for Persons Aged 18-39

The Philippines FDA has reported 361 deaths in persons aged 18-39 as suspected adverse reaction following receipt of Covid-19 injectables. No further by-age breakdowns are available from the Philippines FDA.

VAERS Reports for Filipinos Aged 18 - 39

Breakdowns by vaccine and batches, and age, and types of reactions are all available from the VAERSAWARE database. These only cover Pfizer, Moderna, and Janssen (US Manufactured Products). Limitations on the VAERS foreign data base need to be noted, including incomplete data. It must also be noted that foreign reports only cover events that are categorized as serious. While there is temporality between injection and outcome, generally no causality is acknowledged.

Deaths from Coronavac (Chinese), Sputnik (Russian), AstraZeneca (UK), all non-US manufacturers are not reported in the VAERs system.

Filipinos cannot make direct VAERS reports. Reports are filed by manufacturers after they receive a direct report from Philippines FDA, or from another reporting party.

To summarize the VAERS Filipino Data for persons aged 18 to 39. There were: -

• 2,206 total VAERS ID# counts of suspected SAE.

• These break down to 161 deaths, 27 permanent disabilities, 18 birth defects, 70 life-threatening events, 1,075 hospitalizations, 39 emergency room visits, 749 office visits and 67 reports categorized as “none-of-the-above”. None-of-the-above includes events, which have not been categorized / there is insufficient information provided.

• Other than 712 events with no vaccine batch number provided and 143 events listed as “unknown”, the most common batch numbers with adverse events were FD5996 (Pfizer, incl. 3 deaths), 213C21A (Janssen, incl. 7 deaths), FL5324 (Pfizer, incl. 3 deaths), ACB3221 (Janssen, incl. 5 deaths), FD0350 (Pfizer, incl. 3 deaths), and 212C21A (Janssen, incl. 7 deaths).

• 1,406 events followed injection with the Pfizer product, including 81 deaths and 12 birth defects.

• 417 events followed Moderna, including 43 deaths, and 4 birth defects.

• 383 events followed Janssen, including 37 deaths, and 2 birth defects.

• Injection to onset of symptoms was clustered strongly around the 0 to 1 day post injection.

• In terms of which batch numbers, caused the most deaths in the 18-39 age-group, Janssen led with 4 batches in the top 5 batches identified as responsible for deaths.

• In terms of lag-time between injection and reported suspected related death, there were 90 events where this could be assessed. The most frequent number of days to death from injection were 0 to 2, with small spike on day 6.

Six reports are extracted. There are still 2,200 reports describing death, harm, and serious adverse events.

• 20-year-old male fell unconscious and died the same day that he received a dose of Janssen batch no. 205C21A.

• A 32-year-old female received Janssen ACB3221 on 21 December 2021. She died of a febrile seizure on 23 December 2021.

• 38-year-old man received a second dose of Moderna on 13 September 2021. The patient experienced immediate onset of difficulty breathing, rash, pain in his arm, weakness and increased salivation. He died on 14th September 2021.

• Sudden death from seizure in an 18-year-old female 6 days after she received a dose of Pfizer.

• Life-threatening myocarditis and GERD in a 35-year-old man developed following a first dose and became much worse after a second dose of Pfizer in 2021. Hospitalized and unable to work at the time the report was made. Outcome unknown!

• Guillain Barre Syndrome in a 23-year-old male developed in May 2022, 4-months after a Pfizer booster dose in January 2022. He had received an initial dose of Janssen in August 2021. Hospitalized, intubated in the ICU with his family begging for help as part of their report. Pfizer points to “other suspect drugs”, ie. Janssen as more likely causal than their product. No indication of ultimate outcome is provided!

Recall that massive under-reporting could mean these events are certainly under-reported by a factor of 40x, maybe by 100x or greater.

How can any person with any modicum of common sense maintain that these outcomes have absolutely no relationship to the injectables? How could the Philippines FDA and DOH brazenly continued to push the safe and effective narrative when they were holding such reports in hand since rollout in 2021?

What happened to those who were severely injured? Did they ever get any assistance? Likely not given the measly P100,000K that PHILHEALTH was offering only for persons with knowledge and resources to jump through multiple hoops.

I will continue exploring these VAERS outcomes. I apologize for the somber topic, but this needs to be published.

I hope someone in Philippines mainstream media will be brave enough (and permitted - persons in my network mention first-hand knowledge of journalists and media being incentivized NOT to publish anything negative relating to the rollouts and outcomes) to start speaking out.